Inhibition of brain choline acetyltransferase in vivo: (E)-1-methyl-4-(1-naphthylvinyl)-1,2,3,6-tetrahydropyridine hydrochloride (B115), a depot form of a potent inhibitor.
The quaternary ammonium salt (E)-4-(1-naphthylvinyl)pyridine hydroxyethyl bromide (B111) and the tertiary amine salt (E)-1-methyl-4-(1-naphthylvinyl)-1,2,3,6-tetrahydropyridine hydrochloride (B115), both previously shown to protect against organophosphate (OP) toxicity, were examined in vivo for effects on rat brain choline acetyltransferase (CAT) activity and acetylcholine (ACh) levels. When administered iv, but not when given ip, B111 was able to inhibit brain CAT 29% and reduce brain ACh levels 25%, yet was unable to prevent soman-induced increases in ACh. B115, which may serve as a depot form of a quaternary ammonium analogue, was able to decrease CAT activity as much as 80% upon multiple ip administration. This CAT inhibitory potency was unprecedented for a tertiary amine salt of its structure. However, ACh levels were reduced by no more than 25% and B115 was ineffective in preventing soman- and sarin-induced increases in ACh. Since the degree of inhibition of CAT activity produced by B111 and B115 was not accompanied by a corresponding decrease in ACh levels, the protection afforded by these compounds against OP toxicity is most likely not related to CAT inhibition. B115 was also tested for its ability to affect cholinergic receptor binding. B115 was administered to rats ip, twice daily, at low doses throughout a 3-week period. Analysis of cortex tissue revealed a 45% increase in nicotinic receptor binding with no change in either total muscarinic receptor binding (M-1 and M-2) or high-affinity muscarinic receptor binding (M-2 alone).
Henderson
T R
TR
Department of Pharmacology, Georgetown University Medical Center, Washington, D.C. 20007.
Gray
A P
AP
Platz
R D
RD
Kellar
K J
KJ
Dretchen
K L
KL
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001286:Atropine Derivatives / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D001921:Brain / Q000201:enzymology / Q000378:metabolism; D002795:Choline O-Acetyltransferase / Q000037:antagonists & inhibitors*; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D008297:Male; D009286:Naphthylvinylpyridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D009943:Organophosphorus Compounds / Q000633:toxicity; D010276:Parasympatholytics / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012999:Soman / Q000633:toxicity
D001286:Atropine Derivatives; D001713:Biphenyl Compounds; D003692:Delayed-Action Preparations; D009943:Organophosphorus Compounds; D010276:Parasympatholytics; D010880:Piperidines; C057723:1,1'-((1,1'-biphenyl)-4,4'-diylbis(2-hydroxy-2,1-ethanediyl))bis(1,4-dimethylpiperidinium); C067356:1-methyl-4-(1-naphthylvinyl)-1,2,3,6-tetrahydropyridine hydrochloride; D009286:Naphthylvinylpyridine; C008024:N-(2-hydroxyethyl)-4-(beta-(1-naphthylvinyl)pyridinium bromide); C006649:methylatropine; D012999:Soman; D002795:Choline O-Acetyltransferase; D000109:Acetylcholine